SCHEMBL2700949

SCHEMBL2700949

O=C(Cc1ccc(F)cc1)N1CCC(C(=O)O)(c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.54
POLB P06746 1/20 0.53
KMT2A Q03164 5/20 0.52
TET3 O43151 1/20 0.52
FBXL19 Q6PCT2 1/20 0.52
CXXC5 Q7LFL8 1/20 0.52
TET1 Q8NFU7 1/20 0.52
KDM2B Q8NHM5 1/20 0.52
CXXC4 Q9H2H0 1/20 0.52
KDM2A Q9Y2K7 1/20 0.52
MEN1 O00255 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ME2 P23368 1/20 0.49
ME1 P48163 1/20 0.49
ME3 Q16798 1/20 0.49
MAPT P10636 3/20 0.48
CNR1 P21554 1/20 0.47
PKM P14618 1/20 0.47
ALOX12 P18054 1/20 0.47
AKR1C1 Q04828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2703428 0.87 GFER (0.58) POLBKMT2ATET3FBXL19CXXC5
SCHEMBL2469618 0.86 OPRL1 (0.59) HSD11B1POLBKMT2AMEN1OPRM1
SCHEMBL2468455 0.84 POLB (0.64) POLBKMT2AMEN1NPSR1ME2
SCHEMBL2468188 0.82 CHRM5 (0.48) HSD11B1POLBKMT2AMEN1ALDH1A1
SCHEMBL2702690 0.81 HSD11B1 (0.53) HSD11B1POLBKMT2AMEN1ME2
SCHEMBL2468021 0.80 CHRM5 (0.48) HSD11B1POLBKMT2ANPSR1L3MBTL1
SCHEMBL2467204 0.80 KCNH2 (0.56) KMT2AMEN1MAPTOPRD1OPRM1
SCHEMBL10252749 0.80 NPC1 (0.46) HSD11B1POLBKMT2AMEN1MAPT
SCHEMBL2470391 0.79 KDM4E (0.54) KMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL2473234 0.78 CHRM5 (0.70) KMT2AMEN1MAPTOPRD1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP claimed
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 HSD11B1 4246/4885POLB 4413/4885KMT2A 957/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 HSD11B1 4246/4885POLB 4413/4885KMT2A 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.